Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors

NCT05298176 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

5

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Afatinib, Osimertinib, Carboplatin and Pemetrexed

Sponsor

Amsterdam UMC, location VUmc